Table 2.

Primary efficacy endpoint: clinical success outcome at the end of the study.

Population	Clindamycin [% (95% CI)]	Amoxicillin/clavulanic acid [% (95% CI)]	Treatment difference
			Miettinen and Nurminen method (primary) [% (95% CI)]	Farrington and Manning method [% (95% CI)]	Two-sample proportion test [% (95% CI)]
PP	89.7% (84.6%, 93.5%)	88.2% (83.0%, 92.2%)	1.5% ( 95 CI: −4.7%, 7.7%)	1.5% (−4.9%, 8.0%)	1.5% (−4.5%, 7.6%)
ITT-E	86.4% (81.3%, 90.5%)	85.5% (80.3%, 89.8%)	0.9% (−5.5%, 7.3%)	0.9% (−5.6%, 7.4%)	0.9% (−5.5%, 7.2%)
ITT (randomised treatment arm)	85.7% (80.5%, 89.9%)	83.3% (77.9%, 87.9%)	2.3% (−4.3%, 9.0%)	2.3% (−4.4%, 9.0%)	2.3% (−4.2%, 8.9%)